araag2/HINT huggingface dataset:
Clinical trial NCT00610714 (phase 2, status: completed)
Conditions: ovarian neoplasms, ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: azd0530, carboplatin, paclitaxel
SMILES: CN1CCN(CCOC2=CC3=C(C(NC4=C(Cl)C=CC5=C4OCO5)=NC=N3)C(OC3CCOCC3)=C2)CC1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of advanced ovarian cancer

          -  Have evidence of recurrence or disease progression at least 6 months following
             treatment cessation of 1st or 2nd line platinum containing therapy

          -  Estimated life expectancy of more than 12 weeks

        Exclusion Criteria:

          -  Central Nervous System (CNS) metastases

          -  Received more than 2 prior chemotherapy regimens for ovarian cancer treatment

          -  Inadequate bone marrow reserve

          -  Inadequate liver function, renal function or low haemoglobin

          -  Pregnant, breastfeeding or if of child-bearing status unwilling to use an acceptable
             method of contraception
Clinical trial NCT01102140 (phase 2, status: terminated)
Conditions: cardiomyopathy, heart failure
ICD codes: A36.81, B33.24, I25.5, I42.0, I42.6, I42.9, O90.3, I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: pomx, pomegranate polyphenol extract, sugar pill
SMILES: OC[C@H]1O[C@@](CO)(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@@H](O)[C@@H]1O
Reason stopped: 
    investigator left university of michigan
  
Eligibility criteria:

        Inclusion Criteria:

          -  Adult subjects (≥21 years of age) with cardiomyopathy (ejection fraction ≤40%) of at
             least 1 year duration and CRI (GFR <60 cc/hr for at least 3 months) will be eligible
             for enrollment.

          -  Subjects must have New York Heart Association (NYHA) functional class I-III symptoms
             and be on stable doses of HF evidence-based therapies (β-blocker, ACE inhibitor or
             ARBs, aldosterone inhibitor [if appropriate]) for at least 3 months or have a
             documented contraindication or intolerance to such therapy

        Exclusion Criteria:

          -  Subjects admitted to a hospital for acute myocardial infarction (defined as positive
             troponins) or HF exacerbation within the last 6 months will not be eligible for
             enrollment.

          -  Subjects on warfarin or rosuvastatin will also be excluded.

          -  Other exclusion criteria are as follows:

               -  HF that is deemed to be congenital or infiltrative in etiology

               -  the presence of a life-threatening illness with a projected survival ≤6 months;
                  ongoing infection

               -  pregnancy

               -  inability to follow-up

               -  end-stage renal disease requiring dialysis

               -  renal transplant listing

               -  recent (within last 6 months) POMx use or intake >8 ounces daily of pomegranate
                  juice

               -  known hypersensitivity to any fruit in the Punicaceae family

               -  connective tissue or collagen vascular disease
Clinical trial NCT00330746 (phase 2, status: completed)
Conditions: advanced non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: cetuximab, gemcitabine, gemcitabine, cetuximab
SMILES: [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed written informed consent

          -  Age > 18

          -  Histological diagnosis of non small-cell lung cancer (NSCLC)

          -  Stage III B or Stage IV disease

          -  Contraindications to platinum based therapy (age > 70 or age < 70 with ECOG
             performance status 2)

          -  At least one site of metastasis (target or non-target)

          -  Life expectancy of at least 3 months

          -  ECOG <3

          -  Neutrophils > 1500/mm3, platelets > 100,000/mm3, hemoglobin > 9g/dl

          -  Bilirubin < 1.5 x the upper normal limit

          -  SGOT and SGPT < 2.5 x the upper normal limits (< 5 x the upper normal limit in the
             presence of hepatic metastasis)

          -  Creatinine < 1.5 x the upper normal limit

          -  Adequate method of contraception (male and female), when there is risk of conception.

        Exclusion Criteria:

          -  Symptomatic cerebral metastasis

          -  Previous chemotherapy for advanced disease

          -  Adjuvant chemotherapy within the previous 6 months

          -  Radiation therapy within previous 4 weeks

          -  Any experimental drug therapy within the previous 4 weeks

          -  Previous exposure to monoclonal antibodies, signal transduction inhibitors or EGFR
             targeting therapy

          -  Clinically relevant cardiopathy or myocardial infarct within the last 12 months

          -  Acute or subacute intestinal occlusion or history of inflammatory bowel disease

          -  Known allergy to one or more of the experimental treatments

          -  Known alcohol or substance abuse

          -  Medical or psychological condition which in the opinion of the investigator would not
             permit the patient to complete the study or give informed consent

          -  Pregnant or breastfeeding females

          -  History of malignant neoplasm within the previous 5 years (not including non-melanoma
             skin carcinoma and in-situ carcinoma of the uterine cervix, provided they are being
             adequately treated)
Clinical trial NCT00464347 (phase 2, status: terminated)
Conditions: age-related macular degeneration
ICD codes: H35.3130, H35.3230, H35.3110, H35.3120, H35.3131, H35.3132, H35.3190
Drugs: avastin, preservative-free triamcinolone acetonide (tac-pf)
SMILES: [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Reason stopped: 
    study was terminated because of poor enrollment.
  
Eligibility criteria:

        Inclusion Criteria Includes:

          -  Drusen > 63 mm

          -  Choroidal neovascularization under the fovea (Predominantly Classic, Minimally
             Classic, and Occult lesions acceptable)

          -  Greatest linear dimension (GLD) of entire lesion < 5400 µm (no reading center
             confirmation required)

          -  ETDRS best corrected visual acuity of 20/40 - 20/320 (73 - 24 letter score)

          -  Total area of lesion must < 9 MPS DA

          -  0-3 intravitreal injections of anti-VEGF monotherapy within 6 months of randomization
             with continuing evidence of exudative activity confirmed by FA or OCT within 4-8 weeks
             after the last injection

        Exclusion Criteria Includes:

          -  Oral steroid use within 6 months

          -  Prior complications from steroid therapy

          -  Prior stroke, myocardial infarction, or end-stage malignancy

        Study Eye Exclusion Criteria

          -  Geographic atrophy or fibrosis under the fovea

          -  Fibrosis, hemorrhage, pigment epithelial detachments and other hypofluorescent lesions
             obscuring more than 50% of total lesion

          -  Prior treatment with verteporfin within 12 months

          -  IOP is >25 mmHg and the participant is on Cosopt

          -  Intraocular surgery within 6 weeks

          -  Prior vitrectomy

          -  Peribulbar steroid injection within 6 months

          -  Poor reactions to topical or periocular steroid treatment including elevated IOP
Clinical trial NCT00243503 (phase 2, status: completed)
Conditions: breast neoplasms
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: su011248/trastuzumab
SMILES: CCN(CC)CCNC(=O)C1=C(C)NC(\C=C2/C(=O)NC3=C2C=C(F)C=C3)=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  A diagnosis of breast cancer with evidence of 1) unresectable, locally recurrent, or
             2) metastatic disease.

          -  HER2 positive disease (3+ by immunohistochemistry [IHC] or FISH-positive)

          -  Candidate for treatment with trastuzumab. Prior treatment with trastuzumab and or/
             lapatinib in the neoadjuvant, adjuvant or metastatic disease setting is permitted.
             Treatment with hormone therapy in the adjuvant and/or advanced disease setting is
             permitted.

        Exclusion Criteria:

          -  Prior treatment with >1 regimen of cytotoxic therapy in the advanced disease setting.
             Adjuvant chemotherapy is permitted

          -  Prior exposure to trastuzumab if the patient had developed severe hypersensitivity
             reactions.

          -  Prior treatment on a SU11248 clinical trial.

          -  Uncontrolled brain metastases.
Clinical trial NCT00110344 (phase 2, status: terminated)
Conditions: carcinoma, renal cell
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: nexavar (sorafenib, bay43-9006), placebo
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Life expectancy of at least 12 weeks

          -  Clinical, radiographic, or pathologic diagnosis of metastatic renal cell carcinoma
             (RCC). All renal cell histologies are allowed- Acceptable surgical risk in the
             judgment of the study investigator and consulting urological surgeon

          -  At least one uni-dimensional measurable lesion outside the planned nephrectomy
             specimen

          -  Patients who have an ECOG performance status of 0 or 1 Exclusion Criteria:

          -  History of bleeding diathesis or unexpected surgical bleeding- Patients currently
             receiving treatment with or having a requirement for therapeutic anticoagulation

          -  Prior therapy for RCC. Palliative radiation therapy for painful or unstable bone
             metastases is permitted provided that there is measurable metastatic disease outside
             the radiation field

          -  Known history of HIV infection- Symptomatic metastatic brain or meningeal tumors,
             unless the patient is > 6 months from definitive therapy, has a CT or MRI scan within
             6 weeks of study entry negative for brain metastases and is clinically stable with
             respect to the tumor at the time of study entry
Clinical trial NCT00588666 (phase 2, status: completed)
Conditions: myeloproliferative disorder, urothelial carcinoma, cancer
ICD codes: C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bevacizumab, carboplatin, gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic documentation: diagnosis of transitional cell carcinoma of the
             bladder,urethra, ureter, or renal pelvis.

          -  Unresectable or metastatic disease

          -  Ineligible for cisplatin (or incurable with cisplatin)

          -  ≥ 4 weeks since prior RT

          -  Karnofsky Performance Status ≥ 60%

          -  Age ≥ 18 years of age

          -  Required Initial Laboratory Values: Absolute neutrophil count ≥ 1.2 x 109/L; Platelets
             ≥ 100 x 109/L; Bilirubin ≤ 1.5 times the upper limit of normal (x ULN) for the
             institution; Aspartate transaminase (AST) and alanine transaminase(ALT) ≤ 3.0 x
             ULN;Serum creatinine < 2.0 or calculated creatinine clearance (CrCl) ≥ 30 mL/min

        Exclusion Criteria:

          -  Prior treatment with systemic chemotherapy (prior intravesical therapy is permitted)

          -  Current, recent (within 4 weeks of the first infusion of this study), or planned
             participation in an experimental drug study other than a Genentech-sponsored
             bevacizumab cancer study

          -  Blood pressure of >150/100 mmHg

          -  Unstable angina

          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure

          -  History of myocardial infarction within 6 months

          -  History of stroke within 6 months

          -  Clinically significant peripheral vascular disease

          -  Evidence of bleeding diathesis or coagulopathy

          -  Presence of central nervous system or brain metastases

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0

          -  Anticipation of need for major surgical procedure during the course of the study

          -  Minor surgical procedures such as fine needle aspirations or core biopsies within 7
             days prior to Day 0

          -  Pregnant (positive pregnancy test) or lactating

          -  Albuminuria as demonstrated by a urinary albumin of greater or = to 1.0 g/24 hr at
             screening

          -  History of abdominal fistula, gastrointestinal perforation, or intra abdominal abscess
             within 6 months prior to Day 0

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Inability to comply with study and/or follow-up procedures

          -  History of persistent gross hematuria
Clinical trial NCT00372944 (phase 2, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: azd6244, capecitabine
SMILES: CN1C=NC2=C1C=C(C(O)=NOCCO)C(NC1=C(Cl)C=C(Br)C=C1)=C2F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed with pancreatic cancer

          -  Have failed first line gemcitabine therapy

        Exclusion Criteria:

          -  Previous therapy with EGFR inhibitor, MEK inhibitor or capecitabine.

          -  Any recent surgery, unhealed surgical incision or severe condition such as
             uncontrolled cardiac disease or chronic gastrointestinal diseases.
Clinical trial NCT00467025 (phase 2, status: completed)
Conditions: advanced renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: amg 386, sorafenib, amg 386 placebo iv
SMILES: [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects must have a histologically confirmed metastatic RCC with a clear cell
             component

          -  Low or intermediate risk according to the Memorial Sloan Kettering Cancer Center
             (MSKCC) prognostic risk classification.

          -  Measurable disease with at least one unidimensionally measurable lesion per RECIST
             guidelines with modifications

          -  Adequate organ and hematological function as evidenced by laboratory studies conducted
             at Screening.

          -  ECOG of 0 or 1

        Exclusion Criteria:

        Disease Related

          -  Known history of central nervous system metastases.

          -  Previous treatment (excluding surgery and palliative radiotherapy) for advanced or
             metastatic renal cell carcinoma

          -  Focal radiation therapy for palliation of pain from bony metastases within 14 days of
             randomization.

        Medications

          -  Currently or previously treated with inhibitors of VEGF.

          -  Currently or previously treated with inhibitors of angiopoietin or Tie2.

          -  Currently or previously treated with bevacizumab.

        General Medical

          -  Diagnosis of acute pancreatitis.

          -  Myocardial infarction, cerebrovascular accident, transient ischemic attack,
             percutaneous transluminal coronary angioplasty/stent, congestive heart failure, grade
             2 or greater peripheral vascular disease, arrhythmias not controlled by outpatient
             medication, or unstable angina within 1 year prior to randomization

          -  Major surgery within 30 days before randomization or still recovering from prior
             surgery

          -  Uncontrolled hypertension as defined as diastolic > 90 mmHg OR systolic >150 mmHg.
             Anti-hypertensive medications are permitted.

        Other

          -  Other investigational procedures are excluded

          -  Subject currently is enrolled in or has not yet completed at least 30 days since
             ending other investigational device or drug study(s), or subject is receiving other
             investigational agent(s)
Clinical trial NCT00084435 (phase 2, status: withdrawn)
Conditions: head and neck cancer
ICD codes: C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11
Drugs: cisplatin, docetaxel
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    poor accrual and suspension of head and neck committee
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of squamous cell carcinoma of the head and neck

               -  Selected stage III or IV (no distant metastasis) disease

                    -  The following TNM stages are excluded:

                         -  T3, N0, M0

                         -  T4a, N0, M0

                         -  T4b, N3, M0

                         -  Any T, any N, M1

          -  Complete total resection within the past 56 days AND has one or more of the following
             risk factors:

               -  Multiple pathologically confirmed lymph node metastases

               -  One or more lymph nodes with extracapsular extension of tumor

               -  Microscopically positive margin(s) of resection, including mucosal margins and/or
                  soft tissue or deep margins of resection

          -  No primary nasopharyngeal carcinoma

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  Zubrod 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 8.0 g/dL

        Hepatic

          -  Bilirubin ≤ 2 times upper limit of normal (ULN)

          -  SGOT or SGPT ≤ 1.5 times ULN

          -  Alkaline phosphatase ≤ 2.5 times ULN

        Renal

          -  Creatinine ≤ 1.5 mg/dL OR

          -  Creatinine clearance ≥ 60 mL/min

        Other

          -  No pre-existing peripheral neuropathy

          -  No known history of severe hypersensitiviy reaction to products containing Polysorbate
             80

          -  No other malignancy within the past 5 years except adequately treated basal cell or
             squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated
             stage I or II cancer currently in complete remission

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No prior chemotherapy for the malignancy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  No prior radiotherapy for the malignancy

        Surgery

          -  See Disease Characteristics

        Other

          -  No concurrent amifostine
Clinical trial NCT01366131 (phase 2, status: completed)
Conditions: non-squamous non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: megf0444a, bevacizumab, carboplatin, paclitaxel, placebo
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically documented inoperable (Stage IV) or recurrent
             non-squamous non-small cell lung cancer (NSCLC). Diagnoses of non-squamous NSCLC that
             are based on sputum cytology alone are not acceptable. Mixed tumors should be
             categorized according to the predominant cell type.

          -  ECOG performance status of 0 or 1

          -  Life expectancy >12 weeks

          -  Measurable disease, as defined by RECIST 1.1

          -  Adequate hematologic and end organ function

        Exclusion Criteria:

          -  Prior therapy (including chemotherapy, antibody therapy, tyrosine kinase
             inhibitors,radiotherapy, immunotherapy, hormonal therapy or investigational therapy)
             before Day 1 of Cycle 1 for the treatment of Stage IV or recurrent NSCLC. Patients who
             received prior adjuvant chemotherapy or radiotherapy for NSCLC are not excluded if the
             time interval from completion of adjuvant therapy until disease progression is > 12
             months.

          -  Treatment with any other investigational agent or participation in another clinical
             trial with therapeutic intent within 28 days prior to enrollment

          -  Malignancies other than NSCLC within 5 years prior to randomization, except for
             adequately treated carcinoma in situ of the cervix, basal or squamous cell skin
             cancer, localized prostate cancer treated surgically with curative intent, ductal
             carcinoma in situ treated surgically with curative intent

          -  Pregnant and lactating women

          -  Active infection requiring IV antibiotics

        Bevacizumab-Specific Exclusions:

          -  Histologically or cytologically documented inoperable, locally advanced, mixed
             non-small cell and small cell tumors or mixed adenosquamous carcinomas with a
             predominant squamous component

          -  Evidence of tumor invading major blood vessels on imaging

          -  Evidence of central nervous system (CNS) metastases

          -  History of stroke or transient ischemic attacks (TIAs) within 6 months prior to Day 1

          -  Significant vascular disease within 6 months prior to Day 1

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 1